Entero Therapeutics, Inc. announced a 1 for 3 reverse stock split of its common stock.
The reverse stock split was approved by the Board of Directors and shareholders.
The company expects its common stock to begin trading on a split-adjusted basis on August 18, 2025.
Reverse Stock Split
Every 3 shares will be combined into 1 share, reducing outstanding shares.
Compliance Maintenance
The split is to regain compliance with Nasdaq listing requirement.
CEO's Statement
Richard Paolone sees the split as essential for Nasdaq listing visibility.
- The visibility and credibility of a Nasdaq listing are crucial for shareholder value enhancement.
- The company's outstanding common stock will decrease from around 4.77 million to approximately 1.59 million shares.
The reverse stock split is a strategic move by Entero Therapeutics, Inc. to maintain its Nasdaq listing and enhance shareholder value in the future.